Literature DB >> 3304356

Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens.

W Kenealy, D Reed, R Cybulski, D Tribe, P Taylor, C Stevens, T Matthews, S Petteway.   

Abstract

Recombinant proteins representing gag and env amino acid sequences of the Human Immunodeficiency Virus (HIV) (HTLV-IIIb) were produced in Escherichia coli and used to analyze sera for the presence of antibodies to HIV. ENV-9 is a protein representing the carboxy terminus of gp120 and part of gp41 which is highly immunoreactive. GAG-1 represents 83% and GAG-55 100% of the amino acids of the gag open reading frame. The purified proteins allow sensitive detection by enzyme linked immunosorbent assay (ELISA) of antibodies directed against either env or gag of HIV. We have determined the reactivity of sera from several HIV exposed individuals, either form high risk populations or with clinically defined conditions, in the ENV-9, GAG-55, and GAG-1 assays and found that two major seropositive groups are observed. The quantitative analysis of sera with env and gag antigens by ELISA showed AIDS patients had very low gag reactivity while retaining high env reactivity. Results obtained with authentic p24 viral protein in both ELISA and radioimmunoassay correlated to those from the GAG-55 ELISA. This correlation and the analysis of sera with both the ENV and GAG ELISAs indicate that the antibodies reactive to gag are specifically affected relative to env reactivity and that different levels of antibodies to separate viral components in these sera may correlate with disease state.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304356     DOI: 10.1089/aid.1987.3.95

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Passive hemagglutination test for detection of antibodies to human immunodeficiency virus type 1 and comparison of the test with enzyme-linked immunosorbent assay and Western blot (immunoblot) analysis.

Authors:  M B Vasudevachari; K W Uffelman; T C Mast; R L Dewar; V Natarajan; H C Lane; N P Salzman
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

4.  DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein.

Authors:  M M Rayner; B C Cordova; R P Meade; P E Aldrich; P K Jadhav; Y Ru; P Y Lam
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  Association of human immunodeficiency virus (HIV) p24 antigenemia with decrease in CD4+ lymphocytes and onset of acquired immunodeficiency syndrome during the early phase of HIV infection.

Authors:  C Rinaldo; L Kingsley; J Neumann; D Reed; P Gupta; D Lyter
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

6.  Agreement study between two laboratories of immunofluorescence as a confirmatory test for human immunodeficiency virus type 1 antibody screening.

Authors:  J Mahony; K Rosenthal; M Chernesky; S Castriciano; E Scheid; M Blajchman; D Harnish
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

7.  Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population.

Authors:  D E Tribe; D L Reed; P Lindell; W R Kenealy; B Q Ferguson; R Cybulski; D Winslow; D M Waselefsky; S R Petteway
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

8.  Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.

Authors:  B C Nair; G Ford; V S Kalyanaraman; M Zafari; C Fang; M G Sarngadharan
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

9.  HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Authors:  Marek Malecki; Bianka Saetre
Journal:  Mol Cell Ther       Date:  2018-06-21

Review 10.  The diagnosis of human immunodeficiency virus infection: progress in less than five years.

Authors:  F J Michalski
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.